Ellen ‘t Hoen named one of the “50 Most Influential People in IP”
For Ellen ‘t Hoen's "fierce" advocacy on access to medicine, and in particular for her efforts under the Covid-19 pandemic to ensure knowledge and...
Some Surprises in the European Commission’s New Intellectual Property Strategy
The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...
WTO Members discuss proposal to suspend certain intellectual property protection during the Covid-19 crisis
An earlier version of this comment was published by The Wire on 13 October 2020.
On 2 October, India and South Africa sent a proposal...
How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine
The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not...
TRIPS Council to discuss IP and the public interest in the context of Covid-19
The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...
Remdesivir developed country price announced
On 29, June 2020 Gilead announced its global price for developed countries for remdesivir, a medicine that has shown some effect in the treatment...
COVID-19 Technology Access Pool (C-TAP): A Promising Human Rights Approach
Authors: Katrina Perehudoff and Jennifer Sellin
This article is a reprint, and first appeared on 4 June 2020 in Health and Human Rights.
How do we...
Watch the webinar on the WHO Covid-19 Technology Pool
On 14 May 2020, Medicines Law & Policy together with Health Action International, WEMOS, The Foundation for Pharmaceutical Accountability and Knowledge Ecology International held...
Invitation: 14 May 2020 – The WHO Covid-19 Technology Pool: The solution to ensure...
On 14 May 2020, Health Action International, Knowledge Ecology International, Medicines Law & Policy, Pharmaceutical Accountability Foundation, and Wemos will convene a briefing entitled:...
The € 7.4 billion for Covid-19 product and vaccine development needs a few strings...
On 4 May 2020, European Commission President Ursula von der Leyen hosted the Coronavirus Global Response conference, an on-line pledging event to accelerate the...